AKTX
Price
$1.26
Change
-$0.08 (-5.97%)
Updated
May 9 closing price
Capitalization
36.39M
CANF
Price
$1.11
Change
-$0.01 (-0.89%)
Updated
May 9 closing price
Capitalization
15.07M
Ad is loading...

AKTX vs CANF

Header iconAKTX vs CANF Comparison
Open Charts AKTX vs CANFBanner chart's image
Akari Therapeutics
Price$1.26
Change-$0.08 (-5.97%)
Volume$17.52K
Capitalization36.39M
Can-Fite BioPharma
Price$1.11
Change-$0.01 (-0.89%)
Volume$133.9K
Capitalization15.07M
AKTX vs CANF Comparison Chart
Loading...
AKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKTX vs. CANF commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKTX is a StrongBuy and CANF is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (AKTX: $1.26 vs. CANF: $1.11)
Brand notoriety: AKTX and CANF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKTX: 62% vs. CANF: 38%
Market capitalization -- AKTX: $36.39M vs. CANF: $15.07M
AKTX [@Biotechnology] is valued at $36.39M. CANF’s [@Biotechnology] market capitalization is $15.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKTX’s FA Score shows that 1 FA rating(s) are green whileCANF’s FA Score has 0 green FA rating(s).

  • AKTX’s FA Score: 1 green, 4 red.
  • CANF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKTX is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKTX’s TA Score shows that 4 TA indicator(s) are bullish while CANF’s TA Score has 5 bullish TA indicator(s).

  • AKTX’s TA Score: 4 bullish, 3 bearish.
  • CANF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AKTX and CANF are a good buy in the short-term.

Price Growth

AKTX (@Biotechnology) experienced а -9.99% price change this week, while CANF (@Biotechnology) price change was -1.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

AKTX is expected to report earnings on Apr 15, 2025.

CANF is expected to report earnings on Apr 14, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKTX($36.4M) has a higher market cap than CANF($15.1M). AKTX YTD gains are higher at: 3.287 vs. CANF (-31.692). CANF has higher annual earnings (EBITDA): -7.79M vs. AKTX (-26.82M). CANF has more cash in the bank: 4.73M vs. AKTX (2.25M). CANF has less debt than AKTX: CANF (57K) vs AKTX (1M). CANF has higher revenues than AKTX: CANF (667K) vs AKTX (0).
AKTXCANFAKTX / CANF
Capitalization36.4M15.1M241%
EBITDA-26.82M-7.79M345%
Gain YTD3.287-31.692-10%
P/E RatioN/AN/A-
Revenue0667K-
Total Cash2.25M4.73M48%
Total Debt1M57K1,754%
FUNDAMENTALS RATINGS
AKTX vs CANF: Fundamental Ratings
AKTX
CANF
OUTLOOK RATING
1..100
481
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
6190
P/E GROWTH RATING
1..100
6100
SEASONALITY SCORE
1..100
8595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for AKTX (83) in the Pharmaceuticals Major industry. This means that CANF’s stock grew somewhat faster than AKTX’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to AKTX’s over the last 12 months.

CANF's SMR Rating (95) in the Biotechnology industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to AKTX’s over the last 12 months.

AKTX's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as CANF (90) in the Biotechnology industry. This means that AKTX’s stock grew similarly to CANF’s over the last 12 months.

AKTX's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for CANF (100) in the Biotechnology industry. This means that AKTX’s stock grew significantly faster than CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKTXCANF
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 18 days ago
78%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 17 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
AKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HBAN15.22N/A
N/A
Huntington Bancshares
AAMI29.38-0.12
-0.41%
Acadian Asset Management Inc
CHMG46.03-0.44
-0.95%
Chemung Financial Corp
CLF7.00-0.15
-2.10%
Cleveland-Cliffs
EQ0.39-0.01
-2.13%
Equillium

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.45%
ALDX - CANF
46%
Loosely correlated
+0.93%
OABI - CANF
30%
Poorly correlated
-8.28%
GBIO - CANF
30%
Poorly correlated
+0.06%
TPST - CANF
27%
Poorly correlated
-5.26%
KYTX - CANF
27%
Poorly correlated
-0.94%
More